Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab-Reference-Cited by-同舟云学术

Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab

Published:2009-07 Issue:7 Volume:100 Page:1344-1350
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:

Author:

Tobinai Kensei,Watanabe Takashi,Tanimoto Kazuki,Maruyama Dai,Nakata Masanobu,Itoh Kuniaki,Morishima Yasuo,Ogura Michinori,Usui Noriko,Kasai Masaharu,Terauchi Takashi,Nawano Shigeru,Matsusako Masaki,Matsuno Yoshihiro,Nakamura Shigeo,Mori Shigeo,Ohashi Yasuo

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2009.01162.x/fullpdf

Reference38 articles.

1. Rituximab and other emerging monoclonal antibody therapies for lymphoma;Tobinai;Expert Opin Emerg Drugs,2002

2. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group;Hiddemann;Blood,2005

3. New treatment options have changed the survival of patients with follicular lymphoma;Fisher;J Clin Oncol,2005

4. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma;Marcus;J Clin Oncol,2008

5. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma;Morschhauser;J Clin Oncol,2008

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy;Brain Sciences;2020-08-13

2. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells;Cell Cycle;2018-04-18

3. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas;Clinical Lymphoma Myeloma and Leukemia;2018-01

4. Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials;Journal of Clinical Oncology;2013-11-20

5. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma;European Journal of Haematology;2010-12-29